Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03495336
Other study ID # EasternMedU
Secondary ID
Status Completed
Phase N/A
First received March 17, 2018
Last updated April 4, 2018
Start date March 22, 2017
Est. completion date October 22, 2017

Study information

Verified date April 2018
Source Eastern Mediterranean University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose/Objective: The aim of this study is to investigate the impact of boiled unfiltered (Turkish) coffee consumption on the plasma cardiovascular risk parameters of healthy subjects. The study also explores whether two unfiltered boiled (Turkish) coffee beverages that differ in content due to different roasting degrees will differentially affect cardiovascular biomarkers.

Methods: In this crossover intervention study, healthy, nonsmoking, habitual Turkish coffee drinkers (n=28) were randomized to consume at least 3 cups of Light (LR) or Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks. Subsequent to each coffee abstinence period, both groups received the alternative intervention. After the first WO and the coffee intervention periods, anthropometric measures, blood pressure, heart rate and 13 biochemical parameters were collected and dietary records were completed.


Description:

Background: Considerable controversy exists regarding the link between coffee consumption and cardiovascular disease (CVD) risk. It has been shown that different coffee preparation and brewing methods influence the concentration of compounds present in the final coffee brew. Unlike coffee traditionally consumed in the western world, Turkish coffee is not drip filtered, but rather its method of preparation involves slowly boiling water that is mixed with thinly ground coffee beans. This style of preparation results in a greater amount of biologically active components (caffeine and diterpenes) remaining in the liquid. In addition to preparation styles, roasting process greatly affects the chemical composition of the coffee. Coffee types differing in content of major constituents differ with regard to cardiovascular health effects.

Purpose/Objective: The aim of this study is to investigate the impact of boiled unfiltered (Turkish) coffee consumption on the plasma cardiovascular risk parameters of healthy subjects. The study also explores whether two unfiltered boiled (Turkish) coffee beverages that differ in content due to different roasting degrees will differentially affect cardiovascular biomarkers.

Methods: In this crossover intervention study, healthy, nonsmoking, habitual Turkish coffee drinkers (n=28) were randomized to consume at least 3 cups of Light (LR) or Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks. Subsequent to each coffee abstinence period, both groups received the alternative intervention. After the first WO and the coffee intervention periods, anthropometric measures, blood pressure, heart rate and 13 biochemical parameters were collected and dietary records were completed.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date October 22, 2017
Est. primary completion date June 22, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

- Regular Turkish coffee consumer = 1 cups/day

- Body mass index (BMI) 18.5-24.9 kg/m2 )

- Non-smoker or former smoker (more than a year)

- Willingness to abstain from coffee drinking

- Willingness to consume = 3 cups/day of Turkish coffee

Exclusion Criteria:

- Acute or chronic diseases

- Severe illness with in-patient treatment during last 3 months

- Use of regular medication or any supplements

- Weight reduction ?2 kg/week during the last month

- Pregnancy or breastfeeding

- Regular strong physical activity with =1h/day

- High alcohol intake a weekly intake of ?7 units for women and ?14units for men

- Excess consumption of total fat ?35% of daily calories

- Consumption of saturated fatty acid ?10% of daily calories

- Cholesterol intake ?300mg/day

Study Design


Related Conditions & MeSH terms


Intervention

Other:
coffee abstention phase
no coffee consumption for 2 weeks
LR Coffee consumption
for 4 weeks participants consumed only LR Turkish coffee
DR Coffee consumption
for 4 weeks participants consumed only DR Turkish coffee

Locations

Country Name City State
Cyprus Eastern Mediterrenean University Famagusta

Sponsors (1)

Lead Sponsor Collaborator
Eastern Mediterranean University

Country where clinical trial is conducted

Cyprus, 

Outcome

Type Measure Description Time frame Safety issue
Other Analysis of the content of the diterpenes (cafestol and kahweol) (mg/55mL) in LR and DR Turkish coffee brews Cafestol and kahweol were analyzed in the unsaponified matter by HPLC-DAD. Diterpenes content of the two coffee beverages were reported as mean±standard deviation and Kruskal-Wallis test was used for statistical comparison of coffee roasts.. All analyses were performed using SPSS 24.0 (IBM-SPSS Inc., Chicago, IL, USA). 3 months
Other Analysis of the content of the caffeine (mg/mL) in LR and DR Turkish coffee brews Caffeine was determined by high-performance liquid chromatography (HPLC, Aligent Technologies, USA) with diode-array detector (DAD) and mass spectrometer. content of the two coffee beverages were reported as mean±standard deviation and Kruskal-Wallis test was used for statistical comparison of coffee roasts.. All analyses were performed using SPSS 24.0 (IBM-SPSS Inc., Chicago, IL, USA). 3 months
Primary Comparing the serum lipid levels of all interventions Differences in concentration of serum lipid levels of participants in coffee-free period (washout) and after LR or DR coffee ingestion were measured.
Blood samples were obtained at the end of two weeks washout period and after each four weeks coffee intervention period, and sera were stored at -30° C, until analytical measurements were performed. The levels of serum lipids: Triglycerides (mg/dL), Total cholesterol (mg/dL), and HDL cholesterol (mg/dL) were determined using a Dimension Xpand Plus integrated clinical chemistry autoanalyzer (Siemens Healthcare Diagnostics, Deerfield, IL, USA). The serum levels of LDL cholesterol (mg/dL) were calculated using Friedewald's equation. Differences in blood lipid variables were analyzed by repeated-measures ANOVA for comparisons of LR coffee intake with DR and of each roast with the washout.analyses were performed using SPSS 24.0 (IBM-SPSS Inc., Chicago, IL, USA).
12 weeks
Secondary Comparing the weight (kg) of all interventions Weight was measured after the washout period and after each intervention. Weight (in kilograms) was measured in light clothing, without shoes. 12 weeks
Secondary Comparing the height (cm) of all interventions after the washout period and after each intervention height was measured using a stadiometer to the nearest centimeter. 12 weeks
Secondary Comparing the body mass index (BMI) of all interventions BMI was calculated (weight/height squared; in kilograms per square meter) 12 weeks
Secondary Comparing the body fat percentage (%) of all interventions after the washout period and after each intervention the percentage of body fat and fat free mass (FFM) was measured by Tanita Segmental Body Composition Analyzer BC-418 MA (Tanita Corp. Tokyo, Japan) 12 weeks
Secondary Comparing the waist circumference (cm) of all interventions after the washout period and after each intervention waist circumferences (midway between the rib cage and the iliac crest) were measured using a flexible tape. 12 weeks
Secondary Comparing the blood pressure (BP) (Systolic and Diastolic blood pressure (mmHg)) of all interventions after the washout period and after each intervention BP and heart rate (beats/min) was monitored using an automatic arm sphygmomanometer (Pic Indolor Diagnostic, BS 150, Artsana, Italy) after a 5-min rest in a sitting position. 12 weeks
Secondary Comparing the 3-day food diaries (1 weekend day and 2 weekdays) taken during each intervention Daily nutrient intake was calculated by using computer software (Ebispro, Stuttgart, Germany; Turkish version: BeBiS, Vers. 6.1) 12 weeks
Secondary Comparing the physical activity levels of each intervention The validated Turkish version of the International Physical Activity Questionnaire (IPAQ)-short form (7 item) was administered. The IPAQ questionnaires list activities and request estimates of durations and frequencies for each activity engaged in over the past week. Durations are multiplied by known METs per activity and the results for all items are summed for the overall physical activity score. Scores for walking and for moderate and vigorous activities are sums of corresponding item scores. A sitting question is not included in physical activity score. Physical activity level (PAL): Extremely inactive <1.40 , Sedentary 1.40-1.69, Moderately active 1.70-1.99, Vigorously active 2.00-2.40,Extremely active>2.40 12 weeks
Secondary Comparing the Homocysteine levels of all interventions Differences in concentration of homocysteine (µmol/L) levels of participants after 2wk coffee-free period (washout) and after 4 weeks of LR or DR coffee ingestion was compared. EDTA-treated blood samples for total homocysteine (µmol/L) analysis were immediately refrigerated (placed on ice) until the plasma was separated by centrifugation. All the samples were assayed for Homocysteine by using High Performance Liquid Chromatography with fluorescent detection technique (HPLC-FLD). Differences in homocysteine variables were analyzed by repeated-measures ANOVA for comparisons of LR coffee intake with DR and of each roast with the washout.analyses were performed using SPSS 24.0 (IBM-SPSS Inc., Chicago, IL, USA). 12 weeks
Secondary Comparing the fasting blood glucose levels of all interventions Concentration of fasting blood glucose levels in coffee-free period (washout) and changes after LR or DR coffee ingestion were compared.Blood samples were obtained at the end of two weeks washout period and after each four weeks coffee intervention period, and sera were stored at -30° C, until analytical measurements were performed. The levels of Fasting blood glucose (mg/dL), were determined using a Dimension Xpand Plus integrated clinical chemistry autoanalyzer (Siemens Healthcare Diagnostics, Deerfield, IL, USA). Differences in human variables were analyzed by repeated-measures ANOVA for comparisons of LR coffee intake with DR and of each roast with the washout. 12 weeks
Secondary Comparing the serum Malondialdehyde levels of all interventions Concentration of Serum Malondialdehyde (µM) levels at the end of coffee-free period (washout) and changes after LR or DR coffee ingestion were compared.Serum Malondialdehyde (µM) levels were determined with a colorimetric assay kit (Cayman Chemical, Ann Arbor, MI). Differences in human variables were analyzed by repeated-measures ANOVA for comparisons of LR coffee intake with DR and of each roast with the washout. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)